JP Morgan Chase
AKBA icon

JP Morgan Chase’s Akebia Therapeutics AKBA Stock Holding History

JP Morgan Chase’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$151K Sell
114,047
-79,979
-41% -$110K ﹤0.01% 5619
2025
Q4 		$312K Sell
194,026
-800,155
-80% -$1.68M ﹤0.01% 5292
2025
Q3 		$2.71M Sell
994,181
-658,565
-40% -$2.19M ﹤0.01% 3850
2025
Q2 		$6.02M Buy
1,652,746
+911,585
+123% +$2.5M ﹤0.01% 2987
2025
Q1 		$1.42M Buy
741,161
+284,867
+62% +$581K ﹤0.01% 4107
2024
Q4 		$867K Buy
456,294
+357,748
+363% +$621K ﹤0.01% 4730
2024
Q3 		$130K Buy
98,546
+9,662
+11% +$12.9K ﹤0.01% 5587
2024
Q2 		$90.7K Buy
88,884
+88,653
+38,378% +$110K ﹤0.01% 5566
2024
Q1 		$423 Hold
231
– – ﹤0.01% 6739
2023
Q4 		$286 Sell
231
-94,618
-100% -$96.5K ﹤0.01% 7017
2023
Q3 		$108K Buy
94,849
+56,946
+150% +$73.1K ﹤0.01% 5431
2023
Q2 		$34.7K Sell
37,903
-43,644
-54% -$42.1K ﹤0.01% 5804
2023
Q1 		$45K Buy
81,547
+77,503
+1,916% +$59.2K ﹤0.01% 5733
2022
Q4 		$2K Sell
4,044
-7,347
-64% -$2.3K ﹤0.01% 6287
2022
Q3 		$4K Buy
11,391
+4,171
+58% +$1.64K ﹤0.01% 6125
2022
Q2 		$3K Sell
7,220
-4,250,978
-100% -$1.78M ﹤0.01% 6234
2022
Q1 		$3.06M Sell
4,258,198
-174,005
-4% -$372K ﹤0.01% 3420
2021
Q4 		$10M Sell
4,432,203
-133,532
-3% -$364K ﹤0.01% 2461
2021
Q3 		$13.2M Sell
4,565,735
-382,042
-8% -$1.09M ﹤0.01% 2145
2021
Q2 		$18.8M Buy
4,947,777
+3,744,760
+311% +$12.6M ﹤0.01% 1898
2021
Q1 		$4.07M Sell
1,203,017
-255,807
-18% -$921K ﹤0.01% 3146
2020
Q4 		$4.09M Buy
1,458,824
+1,230,873
+540% +$3.59M ﹤0.01% 2978
2020
Q3 		$544K Sell
227,951
-5,852
-3% -$51.4K ﹤0.01% 3942
2020
Q2 		$3.17M Sell
233,803
-246,194
-51% -$2.55M ﹤0.01% 2794
2020
Q1 		$3.64M Buy
479,997
+192,907
+67% +$1.5M ﹤0.01% 2521
2019
Q4 		$1.81M Sell
287,090
-20,300
-7% -$96.5K ﹤0.01% 3453
2019
Q3 		$1.21M Buy
307,390
+12,577
+4% +$53.9K ﹤0.01% 3725
2019
Q2 		$1.36M Buy
294,813
+14,869
+5% +$84.6K ﹤0.01% 3653
2019
Q1 		$2.29M Sell
279,944
-1,384
-0.5% -$9.5K ﹤0.01% 3239
2018
Q4 		$1.55M Sell
281,328
-24,365
-8% -$191K ﹤0.01% 3459
2018
Q3 		$2.7M Buy
305,693
+8,747
+3% +$78.2K ﹤0.01% 3245
2018
Q2 		$2.96M Buy
296,946
+25,273
+9% +$253K ﹤0.01% 3102
2018
Q1 		$2.59M Sell
271,673
-14,584
-5% -$204K ﹤0.01% 3085
2017
Q4 		$4.26M Buy
+286,257
New +$4.75M ﹤0.01% 2808
2017
Q2 		– Sell
-12,650
Closed -$117K – 4929
2017
Q1 		$117K Sell
12,650
-42,718
-77% -$417K ﹤0.01% 4263
2016
Q4 		$576K Buy
+55,368
New +$477K ﹤0.01% 3694
2016
Q3 		– Sell
-1,292
Closed -$10K – 4511
2016
Q2 		$10K Buy
1,292
+788
+156% +$6.88K ﹤0.01% 4339
2016
Q1 		$5K Buy
504
+369
+273% +$2.99K ﹤0.01% 4357
2015
Q4 		$2K Buy
+135
New +$1.38K ﹤0.01% 4506

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase's AKBA Position: Q1 2026 in Review

JP Morgan Chase reduced its Akebia Therapeutics (AKBA) stake by 41% in Q1 2026, selling an estimated $110K and leaving 114,047 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #5619.

JP Morgan Chase first reported a position in AKBA in Q4 2015 and has held it in 39 quarters since. The position peaked at $18.8M in Q2 2021. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • JP Morgan Chase held 114,047 shares of Akebia Therapeutics worth $151K as of Q1 2026.
  • JP Morgan Chase sold 79,979 Akebia Therapeutics shares in Q1 2026, an estimated $110K.
  • Akebia Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5619 holding.
  • JP Morgan Chase first reported a position in Akebia Therapeutics in Q4 2015 and has held it in 39 quarters since.
  • JP Morgan Chase's Akebia Therapeutics position peaked at $18.8M in Q2 2021.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.